Highly sweetened, flavored alcoholic drinks, often marketed in brightly colored portable containers, may deserve greater attention from hepatologists because they combine concentrated alcohol exposure with substantial metabolic stress, experts warned.
“What hepatologists are telling us is that more and more patients are coming into clinic where the problem is no longer alcohol or sugar, it’s both together. It’s an engineered exposure, where alcohol and sugar are being delivered into the body at the same time,” said Catherine Paradis, PhD, technical officer and sociologist at World Health Organization (WHO) Europe, speaking with Medscape News Europe.
“The liver is being punched twice,” she said. “The alcohol is directly toxic to the liver, while at the same time contributing excess calories and metabolic stress.”
Paradis delivered a presentation on the health threat of metabolic dysfunction-associated alcohol-related liver disease (MetALD) and sweetened alcoholic beverages at the European Association for the Study of the Liver (EASL) Congress 2026.
Engineered for Commercial Success, Health Failure
MetALD describes liver disease in individuals with metabolic risk factors who also consume harmful levels of alcohol. The category reflects growing recognition that obesity, fatty liver disease, diabetes, and alcohol exposure frequently interact rather than operate as separate causes of liver injury, explained Paradis.
The issue is not simply that people are exposed to alcohol and sugar, she noted, but that the exposure itself has been “optimized” through product design, packaging, flavoring, and marketing. She argued that hepatologists need to look beyond MetALD as a clinical phenotype, and to consider how commercial environments can shape exposure to it. “If alcohol and metabolic dysfunction are converging in patients, what is happening outside the clinic that is making those convergences more likely?” she asked.
Products Designed for Rapid Consumption
Paradis specifically described a popular brand of on-the-go, single-serve cocktails packaged in highly colorful, spherical containers that are sold in many countries around the world.
One container contains approximately 23.7 g of alcohol, equivalent to more than two standard drinks in many European countries and close to three UK alcohol units, according to data presented during the session. A single container also has approximately 24 g of sugar.
“Their sweetness masks the taste of alcohol, while their size and design make repeated consumption easier,” Paradis said. “These are extremely potent products disguised as sweetened soft drinks.”
She argued that the issue is not simply alcohol concentration itself, but how the drinks are formulated, packaged, and marketed. “The drinking patterns that emerge from these products are not accidental,” she said. “They are shaped by product design.”
Drawing on addiction science, Paradis said such products may increase reinforcement through dose optimization, speed of delivery, sensory engineering, environmental ubiquity, and repeated reformulation.
“If we ignore the product design, we risk reducing the discussion to willpower, more discipline, better choices, more individual responsibility; and that would be wrong,” she said
Regulatory Loopholes
Paradis also highlighted regulatory concerns surrounding flavored alcoholic beverages that may not fit neatly into traditional categories such as beer, spirits, or soft drinks despite delivering substantial alcohol loads.
“Many of these products are not quite spirits, they are not quite soft drinks,” she said. “They may be sold, packaged, promoted, and taxed in ways that do not reflect the dose of ethanol they deliver. They borrow from the sensory world of soft drinks while carrying the risks of alcohol.”
In some countries, manufacturers have reformulated products from spirit-based to malt-based beverages, allowing them to be sold more cheaply, in more venues, or under different tax arrangements, she said, adding that “product innovation exploits gaps between policy categories.”
Paradis cited recent UK reporting suggesting that retail sales of premium, ready-to-drink cocktails rose by around 30% between January and March 2026, describing this as “a useful signal of how fast these formats are moving.”
Clinicians See the Consequences
Commenting for Medscape News Europe, Zobair Younossi, MD, MPH, professor at Georgetown University School of Medicine, Washington, DC, said the clinical concern is particularly acute because obesity and type 2 diabetes are rising rapidly, including in children.
“The burden, the tsunami that is coming, will be from the kids,” he said. “The problem of obesity has increased tremendously, and the prevalence of type 2 diabetes has increased tremendously in children.”
He stressed that highly sweetened alcoholic products could add a second liver insult. “If there is also the second added damage from alcohol, often sweetened alcohol use by kids, then I think we will see much more impact of these diseases in the future unless we do something about it.”
He explained that sugar can promote excess calorie intake, obesity, and metabolic dysfunction, whereas alcohol may further amplify liver injury. “You have that double damaging of obesity and cytokines hitting the liver,” he said. “And now you have alcohol that actually exacerbates that and causes more damage.”
Paradis said hepatologists are not responsible for designing, taxing, or regulating such products, but they are often the first to see the clinical consequences. “You see the harms,” she told delegates. “You see the younger patients. You see the interaction between alcohol and metabolic dysfunction before it becomes visible to policy leaders.”
Policy Measures and Prevention
The WHO does not take positions on individual commercial products, Paradis said, but maintains that no level of alcohol consumption can be considered completely risk-free for health.
“That is not the same as promoting prohibition or abstinence,” she said. “It simply means that any level of alcohol carries some degree of risk.”
At policy level, the WHO supports measures to reduce alcohol affordability, availability, and advertising, often referred to as alcohol policy “best buys.” Paradis said policy should also address product design where design itself increases the risk.
She appealed to hepatologists to engage more actively in alcohol policy discussions. “Hepatologists have unique power,” she said. “Alcohol control is disease prevention.”
“If we accept that MetALD reflects convergence between alcohol and metabolic dysfunction,” Paradis concluded, “then prevention must also address the environments where alcohol exposure is produced. Otherwise, hepatology will continue to respond downstream while upstream exposure continues to expand.”
Paradis reported having no relevant financial relationships. Younossi reported having research and consulting relationships with Madrigal, Ipsen, and other companies in the field.
https://www.medscape.com/viewarticle/alcohol-sugar-double-whammy-coming-patients-near-you-2026a1000hxb
